Drug Trial Radar · NCT05999357
JDQ443 for KRAS G12C NSCLC Brain Metastases
Last checked: Nov 19, 2026Latest source record: May 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Apr 15, 2024
Primary completion
Aug 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- Maastricht University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this phase II clinical trial is to evaluate the intracranial efficacy of JDQ443, a KRAS G12C inhibitor in patients with KRAS G12C+ NSCLC and brain metastases (cohort A: asymptomatic, untreated brain metastases, cohort B: asymptomatic, treated brain metastases). The main question it aims to answer is to evaluate the intracranial efficacy, according to RANO-BM criteria, in patients with asymptomatic and untreated brain metastases. Participants will receive JDQ443 200 mg BID until unacceptable toxicity or disease progression.
Conditions
- Non Small Cell Lung Cancer Metastatic
- Brain Metastases, Adult
- KRAS G12C
Interventions
JDQ443Drug
JDQ443 tablets, orally administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- brain metastases overall response rate (ORR)Time frame: up to 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.